A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference

Paulus Kirchhof*, Guenter Breithardt, Jeroen Bax, Gerlinde Benninger, Carina Blomstrom-Lundqvist, Giuseppe Boriani, Axel Brandes, Helen Brown, Martina Brueckmann, Hugh Calkins, Melanie Calvert, Vincent Christoffels, Harry Crijns, Dobromir Dobrev, Patrick Ellinor, Larissa Fabritz, Thomas Fetsch, S. Ben Freedman, Andrea Gerth, Andreas GoetteEduard Guasch, Guido Hack, Laurent Haegeli, Stephane Hatem, Karl Georg Haeusler, Hein Heidbuechel, Jutta Heinrich-Nols, Francoise Hidden-Lucet, Gerd Hindricks, Steen Juul-Moeller, Stefan Kaeaeb, Lukas Kappenberger, Stefanie Kespohl, Dipak Kotecha, Deirdre A. Lane, Angelika Leute, Thorsten Lewalter, Ralf Meyer, Lluis Mont, Felix Muenzel, Michael Nabauer, Jens C. Nielsen, Michael Oeff, Jonas Oldgren, Ali Oto, Jonathan P. Piccini, Art Pilmeyer, Tatjana Potpara, Ursula Ravens, Holger Reinecke, Thomas Rostock, Joerg Rustige, Irene Savelieva, Renate Schnabel, Ulrich Schotten, Lars Schwichtenberg, Moritz F. Sinner, Gerhard Steinbeck, Monika Stoll, Luigi Tavazzi, Sakis Themistoclakis, Hung Fat Tse, Isabelle C. Van Gelder, Panagiotis E. Vardas, Timo Varpula, Alphons Vincent, David Werring, Stephan Willems, Andre Ziegler, Gregory Y. H. Lip, A. John Camm

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and many more suffer from undiagnosed, subclinical, or 'silent' AF. Atrial fibrillation-related cardiovascular mortality and morbidity, including cardiovascular deaths, heart failure, stroke, and hospitalizations, remain unacceptably high, even when evidence-based therapies such as anticoagulation and rate control are used. Furthermore, it is still necessary to define how best to prevent AF, largely due to a lack of clinical measures that would allow identification of treatable causes of AF in any given patient. Hence, there are important unmet clinical and research needs in the evaluation and management of AF patients. The ensuing needs and opportunities for improving the quality of AF care were discussed during the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference in Nice, France, on 22 and 23 January 2015. Here, we report the outcome of this conference, with a focus on (i) learning from our 'neighbours' to improve AF care, (ii) patient-centred approaches to AF management, (iii) structured care of AF patients, (iv) improving the quality of AF treatment, and (v) personalization of AF management. This report ends with a list of priorities for research in AF patients.
Original languageEnglish
Pages (from-to)37-50
JournalEP Europace
Volume18
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • Atrial fibrillation
  • Outcomes
  • Quality of care
  • Research
  • Rate control
  • Antiarrhythmic drugs
  • Catheter ablation
  • Anticoagulation
  • Cardiovascular risk
  • Bleeding
  • Research priorities

Cite this